Subscribe to Newsletter
Inside the Lab Point of care testing, Technology and innovation

Good on Paper

Approximately 70 percent of all clinical decisions and therapeutic treatments are based on the results of a diagnostic assay, but they account for only 2.3 percent of the total medical costs of treating a patient in the United States (1). Diagnostic assays play an even more critical role in remote, resource-limited settings where doctors or other trained medical personnel are not available (2). In these settings, a reliable diagnostic could mean the difference between life and death; millions of people in developing countries die every year from preventable or treatable diseases, at least in part because appropriate assays are not available (3). In resource-limited environments, most existing technologies are either too expensive or not compatible with the extreme conditions encountered (4). Low-cost, point-of-care tests (POCTs) have the potential to overcome both of these challenges if developed appropriately – and some, such as the rapid test for malaria, have already had an impact, leading to a significant reduction in the burden of disease around the globe (3). With appropriate design, next generation POCTs could lead to further improvements in global health.

A POCT is the combination of assay chemistry and a platform (i.e., a device) to support that chemistry. To be useful in resource-limited environments, the device must be cheap, small and portable; the reagents must be stable at room temperature; the results of the assay chemistry need to be accurate and easy to interpret; the assay should have minimal power requirements (ideally, the assay should not require electrical power, but battery-powered assays are an option); and the assay should be relatively simple to perform – ideally, the user must only apply the sample to the device and then read the results. The WHO released the “ASSURED” criteria to describe the perfect assay: affordable, sensitive, specific, user-friendly, rapid, equipment-free and deliverable to end-users. Paper-based platforms were developed specifically to meet the demands of resource-limited settings.

The potential benefits of new diagnostic technologies easily justify the investment in time and resources required to develop them.

Paper has many inherent characteristics that make it well-suited as a platform for POCTs – it is cheap and widely available, it wicks fluids by capillary action, it has a large surface-to-volume ratio, and it provides a white background that makes color changes easy to see. The first examples of paper-based devices were simple dipstick assays (like litmus paper) that monitored the concentrations of certain analytes using color changes. Then came lateral-flow immunoassays, such as the rapid diagnostic test for malaria and the home pregnancy test, which vastly expanded the range of analytes that could be detected on paper by relying on antibodies for detection. A global community of researchers is now working on the next generation of paper-based devices known as microfluidic paper-based analytical devices, or microPADs.

A reliable diagnostic could mean the difference between life and death.

MicroPADs are devices made from paper or other porous membranes, patterned with hydrophobic inks to create hydrophilic channels. Like conventional microfluidic devices made from glass or plastic, microPADs comprise a network of channels that can be used to process small volumes of sample and perform multiplexed assays. Unlike conventional microfluidic devices, microPADs wick fluids by capillary action, so they don’t rely on pumps or other supporting equipment. The combination of microPADs with new assay chemistries is leading to more sensitive and quantitative assays that should expand the applications and utility of paper-based tests (4).

Though POCTs for use in resource-limited settings must be cheap, rapid and simple, the process of developing these devices is challenging, expensive and time-consuming. However, the potential benefits of new diagnostic technologies easily justify the investment in time and resources required to develop them. And who knows – the device originally developed to use in rural villages could one day end up serving the populations of major cities too.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. UP Rohr et al., “The value of in vitro diagnostic testing in medical practice: a status report”, PLoS One, 11, e0149856 (2016). PMID: 26942417.
  2. D Mabey et al., “Diagnostics for the developing world”, Nat Rev Microbiol, 2, 231–240 (2004). PMID: 15083158.
  3. AN Abou Tayoun et al., “Democratizing molecular diagnostics for the developing world”, Am J Clin Pathol, 141, 17–24 (2014). PMID: 24343733.
  4. AK Yetisen et al., “Paper-based microfluidic point-of-care diagnostic devices”, Lab Chip, 13, 2210–2251 (2013). PMID: 23652632.
About the Author
Andres Martinez

Andres Martinez is Associate Professor of Chemistry at California Polytechnic State University, San Luis Obispo, USA.


Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine